Molecular Insight into the Therapeutic Promise of Targeting<i>APOE4</i>for Alzheimer’s Disease

Mamun, Abdullah Al; Uddin, Sahab; Bashar, Fahim Bin; Zaman, Sonia; Begum, Yesmin; Bulbul, Israt Jahan; Islam, Saiful; Sarwar, Shahid; Mathew, Bijo; Amran, Shah; Ashraf, Ghulam Md; Bin-Jumah, May; Mousa, Shaker A.; Abdel-Daim, Mohamed M.

doi:10.1155/2020/5086250

Cited by 40 publications

(25 citation statements)

References 197 publications

(201 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dysregulated expression of these genes might be present in around 5–10% of diagnosed cases of early-onset AD [ 4 , 6 ]. Indeed, apolipoprotein E (APOE) polymorphic alleles play a significant role in the development of early-onset and late-onset AD [ 7 , 8 ]. In addition, the presence of APOE4 alleles is linked with an elevated risk of cerebral amyloid angiopathy and age-associated cognitive deficit during normal aging [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Anti-Alzheimer’s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential

et al. 2021

Self Cite

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the most common cause of dementia. It has been confirmed that the pathological processes that intervene in AD development are linked with oxidative damage to neurons, neuroinflammation, tau phosphorylation, amyloid beta (Aβ) aggregation, glutamate excitotoxicity, and cholinergic deficit. Still, there is no available therapy that can cure AD. Available therapies only manage some of the AD symptoms at the early stages of AD. Various studies have revealed that bioactive compounds derived from marine organisms and plants can exert neuroprotective activities with fewer adverse events, as compared with synthetic drugs. Furthermore, marine organisms have been identified as a source of novel compounds with therapeutic potential. Thus, there is a growing interest regarding bioactive compounds derived from marine sources that have anti-AD potentials. Various marine drugs including bryostatin-1, homotaurine, anabaseine and its derivative, rifampicins, anhydroexfoliamycin, undecylprodigioisin, gracilins, 13-desmethyl spirolide-C, and dictyostatin displayed excellent bioavailability and efficacy against AD. Most of these marine drugs were found to be well-tolerated in AD patients, along with no significant drug-associated adverse events. In this review, we focus on the drugs derived from marine life that can be useful in AD treatment and also summarize the therapeutic agents that are currently used to treat AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-Alzheimer’s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…As stated earlier, atypical production and accumulation of Aβ peptides in the brain are considered as the hallmark of AD ( Al Mamun et al., 2020a ; Sharma et al., 2020 ; Uddin et al., 2020i ). Exogenous cannabinoids, a neuroprotective agent, have persistently been disclosed to restrain memory deficits in Aβ-treated animal models for both synthetic selective cannabinoid receptors agonists ( Haghani et al., 2012 ; Wang et al., 2013 ), as well as mixed cannabinoid receptors agonists ( Ramírez et al., 2005 ; Martín-Moreno et al., 2011 ; Fakhfouri et al., 2012 ) and natural CBD ( Martín-Moreno et al., 2011 ).…”

Section: Effect Of Cannabinoids On Alzheimer’s Hallmarksmentioning

confidence: 99%

Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer’s Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

Alzheimer's disease (AD) is an irreversible chronic neurodegenerative disorder that occurs when neurons in the brain degenerate and die. Pain frequently arises in older patients with neurodegenerative diseases including AD. However, the presence of pain in older people is usually overlooked with cognitive dysfunctions. Most of the times dementia patients experience moderate to severe pain but the development of severe cognitive dysfunctions tremendously affects their capability to express the presence of pain. Currently, there are no effective treatments against AD that emphasize the necessity for increasing research to develop novel drugs for treating or preventing the disease process. Furthermore, the prospective therapeutic use of cannabinoids in AD has been studied for the past few years. In this regard, targeting the endocannabinoid system has considered as a probable therapeutic strategy to control several associated pathological pathways, such as mitochondrial dysfunction, excitotoxicity, oxidative stress, and neuroinflammation for the management of AD. In this review, we focus on recent studies about the role of cannabinoids for the treatment of pain and related neuropathological changes in AD.

show abstract

“…The three isoforms differ only by a single amino acid substitution, leading to altered protein structure and correlated biological functions. Specifically, the APOE4 allele is widely known to be one of the strongest risk factors for developing AD [54], while APOE2 has shown neuroprotective effects [55].…”

Section: Apolipoprotein Ementioning

confidence: 99%

HDL Proteome and Alzheimer’s Disease: Evidence of a Link

et al. 2020

View full text Add to dashboard Cite

Several lines of epidemiological evidence link increased levels of high-density lipoprotein-cholesterol (HDL-C) with lower risk of Alzheimer’s disease (AD). This observed relationship might reflect the beneficial effects of HDL on the cardiovascular system, likely due to the implication of vascular dysregulation in AD development. The atheroprotective properties of this lipoprotein are mostly due to its proteome. In particular, apolipoprotein (Apo) A-I, E, and J and the antioxidant accessory protein paraoxonase 1 (PON1), are the main determinants of the biological function of HDL. Intriguingly, these HDL constituent proteins are also present in the brain, either from in situ expression, or derived from the periphery. Growing preclinical evidence suggests that these HDL proteins may prevent the aberrant changes in the brain that characterize AD pathogenesis. In the present review, we summarize and critically examine the current state of knowledge on the role of these atheroprotective HDL-associated proteins in AD pathogenesis and physiopathology.

show abstract

Molecular Insight into the Therapeutic Promise of TargetingAPOE4for Alzheimer’s Disease

Cited by 40 publications

References 197 publications

Anti-Alzheimer’s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential

Anti-Alzheimer’s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential

Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer’s Disease

HDL Proteome and Alzheimer’s Disease: Evidence of a Link

Contact Info

Product

Resources

About